National Institute for Communicable Diseases, South Africa Report issue

Government Phase 3

Organization Overview

First Clinical Trial
2005
NCT00164424
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

National Institute for Communicable Diseases, South Africa | National Institute of Communicable Diseases - NICD | STIRC, National Institute for Communicable Diseases (NICD), South Africa

Active Ingredients

Drugs in Phase 3 Trials (2)

aciclovir (zovirax) (1 trial)

janssen SARS-CoV2 vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Herpes Simplex (Phase 3)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2